Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 24: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty
Author(s): Ulf Teichgräber Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of the trial shows that percutaneous transluminal angioplasty (PTA) with the sirolimus drug coated balloon (DCB) in patients with femoropopliteal artery disease was/was not noninferior to PTA with the paclitaxel DCB.Prof Ulf Teichgräber joins us onsite at TCT Conference to discuss the findings from the sirolimus- vs. paclitaxel-coated balloon… View more

Intervention

Vascular Disease and Surgery
TCT 2025: SELUTION DeNovo: 1-Year Results Comparing Sirolimus Balloon vs DES in PCI
Author(s): Christian Spaulding Added: 3 months ago
TCT 2025 — Prof Christian M Spaulding (European Hospital Georges Pompidou & INSERM U 970, FR), principal investigator of the SELUTION DeNovo trial (M.A. Med Alliance S.A.; NCT04859985), joins us to share the one year results.This international, multicentre randomised trial enrolled over 3,300 patients at 50 sites across Europe and Asia to compare a sirolimus-eluting balloon (SEB) plus provisional… View more

Intervention
TCT 2024 Late-Breaking Science Collection
Author(s): Dr Wissam A Jaber Added: 1 year ago
Keep informed with our video collection unveiling data from the Transcatheter Cardiovascular Therapeutics Conference in Washington. With expert insights on late-breaking trials and critical findings, you won't want to miss our #TCT24 coverage.For practice-focused reviews of the most anticipated trials, watch our recurring View From the Thoraxcenter series, hosted byProf Nicolas Van Mieghem and Dr… View more

Intervention
EuroPCR 24: The ABILITY Study
Author(s): Roxana Mehran Added: 1 year ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary… View more

Intervention
TCT 2025 Late-Breaking Science Collection
Author(s): Michael J Mack Added: 3 months ago
Stay Updated with Our TCT 2025 Video CoverageWe’re bringing you independent, critical insights straight from TCT 2025.Join Prof Nicolas Van Mieghem in Cardiology Conference Perspectives as he discusses what the late-breaking data could mean for your practice.Don’t miss our short Expert Interviews with investigators, offering concise analyses and practical take-home messages.Hear Dr Mirvat Alasnag… View more

Intervention
TCT 2025: INFINITY-SWEDEHEART: Long-Term Bioadaptor Outcomes
Author(s): David Erlinge Added: 3 months ago
TCT 2025 - Findings from INFINITY-SWEDEHEART show significant reductions in target vessel failure and treatment benefit after 6 months to two years with the DynamX bioadaptor stent.Prof David Erlinge (Skane University Hospital, SE) joins us to discuss findings from the INFINITY-SWEDEHEART trial, a prospective, multicenter, registry-based randomized clinical trial comparing long-term outcomes of… View more

Intervention

MI/ACS
View from the Thoraxcenter: ESC 23 Late-breaking Science Wrap Up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 2 years ago
What are the take-home messages from ESC 2O23? Join us as we delve into the pivotal results that ignited debates and discussions at ESC Congress 2023. Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) return with their "View from the Thoraxcenter" review, where they analyse the hot line and late-breaking trials presented in Amsterdam. In this ESC 2023… View more

Anticoagulation

Guidelines & Statements
Management of Left Main Coronary Artery Disease
Author(s): Gabriel Torres-Ruiz , Nuria Mallofré-Vila , Paola Rojas-Flores , et al Added: 2 years ago

Intervention

Prevention & Chronic Conditions